AKT

Timothy A. Yap; Johann S. de Bono

doi:10.1007/978-1-4419-0717-2_35

AKT

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

AKT, also known as protein kinase B and RAC-PK, was first discovered as an oncogene transduced by the acute transforming retrovirus (AKT-8), which is known to cause leukemia in mice. AKT is the major downstream target of phosphatidylinositol 3-kinase (PI3K), which can be activated by receptor tyrosine kinases in response to various growth factors. AKT is a serine/threonine kinase located at the apex of a cascade of signaling pathways. Deregulated AKT signaling is implicated in cancer cell growth, proliferation, and survival. Novel antitumor strategies have now been developed to target AKTand key downstream targets in the clinic.

Original language	English (US)
Title of host publication	Cancer Therapeutic Targets
Publisher	Springer New York
Pages	3-12
Number of pages	10
Volume	1-2
ISBN (Electronic)	9781441907172
ISBN (Print)	9781441907165
DOIs	https://doi.org/10.1007/978-1-4419-0717-2_35
State	Published - Jan 1 2017
Externally published	Yes

Keywords

A-443654
AKT
Assessment
AT13148
AT7867
CCT128930
Fluorescence in situ hybridization (FISH)
GSK690693
Phosphatidylinositol 3-kinase (PI3K)
Predictive biomarkers
Protein kinase B. See AKT
Therapeutics

ASJC Scopus subject areas

General Medicine
General Biochemistry, Genetics and Molecular Biology
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.1007/978-1-4419-0717-2_35

Cite this

@inbook{fcb30f306f0a4d679b559836e347eef5,

title = "AKT",

abstract = "AKT, also known as protein kinase B and RAC-PK, was first discovered as an oncogene transduced by the acute transforming retrovirus (AKT-8), which is known to cause leukemia in mice. AKT is the major downstream target of phosphatidylinositol 3-kinase (PI3K), which can be activated by receptor tyrosine kinases in response to various growth factors. AKT is a serine/threonine kinase located at the apex of a cascade of signaling pathways. Deregulated AKT signaling is implicated in cancer cell growth, proliferation, and survival. Novel antitumor strategies have now been developed to target AKTand key downstream targets in the clinic.",

keywords = "A-443654, AKT, Assessment, AT13148, AT7867, CCT128930, Fluorescence in situ hybridization (FISH), GSK690693, Phosphatidylinositol 3-kinase (PI3K), Predictive biomarkers, Protein kinase B. See AKT, Therapeutics",

author = "Yap, {Timothy A.} and {de Bono}, {Johann S.}",

year = "2017",

month = jan,

day = "1",

doi = "10.1007/978-1-4419-0717-2_35",

language = "English (US)",

isbn = "9781441907165",

volume = "1-2",

pages = "3--12",

booktitle = "Cancer Therapeutic Targets",

publisher = "Springer New York",

address = "United States",

}

TY - CHAP

T1 - AKT

AU - Yap, Timothy A.

AU - de Bono, Johann S.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - AKT, also known as protein kinase B and RAC-PK, was first discovered as an oncogene transduced by the acute transforming retrovirus (AKT-8), which is known to cause leukemia in mice. AKT is the major downstream target of phosphatidylinositol 3-kinase (PI3K), which can be activated by receptor tyrosine kinases in response to various growth factors. AKT is a serine/threonine kinase located at the apex of a cascade of signaling pathways. Deregulated AKT signaling is implicated in cancer cell growth, proliferation, and survival. Novel antitumor strategies have now been developed to target AKTand key downstream targets in the clinic.

AB - AKT, also known as protein kinase B and RAC-PK, was first discovered as an oncogene transduced by the acute transforming retrovirus (AKT-8), which is known to cause leukemia in mice. AKT is the major downstream target of phosphatidylinositol 3-kinase (PI3K), which can be activated by receptor tyrosine kinases in response to various growth factors. AKT is a serine/threonine kinase located at the apex of a cascade of signaling pathways. Deregulated AKT signaling is implicated in cancer cell growth, proliferation, and survival. Novel antitumor strategies have now been developed to target AKTand key downstream targets in the clinic.

KW - A-443654

KW - AKT

KW - Assessment

KW - AT13148

KW - AT7867

KW - CCT128930

KW - Fluorescence in situ hybridization (FISH)

KW - GSK690693

KW - Phosphatidylinositol 3-kinase (PI3K)

KW - Predictive biomarkers

KW - Protein kinase B. See AKT

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85038906054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038906054&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0717-2_35

DO - 10.1007/978-1-4419-0717-2_35

M3 - Chapter

AN - SCOPUS:85038906054

SN - 9781441907165

VL - 1-2

SP - 3

EP - 12

BT - Cancer Therapeutic Targets

PB - Springer New York

ER -

AKT

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this